DGAP-News: WILEX AG: Professor Olaf G. Wilhelm leaves the Executive Management Board on 31 March 2014, Dr Jan Schmidt-Brand will

DGAP-News: WILEX AG: Professor Olaf G. Wilhelm leaves the Executive Management 
Board on 31 March 2014, Dr Jan Schmidt-Brand will lead the Company

DGAP-News: WILEX AG / Key word(s): Change of Personnel
WILEX AG: Professor Olaf G. Wilhelm leaves the Executive Management
Board on 31 March 2014, Dr Jan Schmidt-Brand will lead the Company

24.02.2014 / 21:50



Professor Olaf G. Wilhelm leaves the Executive Management Board on 31 March
2014, Dr Jan Schmidt-Brand will lead the Company

Munich, Germany, 24 February 2014. WILEX AG (ISIN DE0006614720/ WL6 / FSE)
today announced that Professor Olaf G. Wilhelm will step down as Chairman
of the Executive Management Board when his director's contract expires on
31 March 2014.

As a co-founder of the company (1997) and Chief Executive Officer of WILEX
AG since 2001, Professor Wilhelm will leave the Company in view of the
future direction of the company and the necessary adjustments by mutual
consent with the Supervisory Board and maintains a good relationship with
his colleagues. The Supervisory Board of WILEX AG thanks Professor Wilhelm
for his many years of service, his entrepreneurship and his great
dedication to WILEX.

Dr Jan Schmidt-Brand, who has been the company's Chief Financial Officer
since 2012, will lead the Executive Management Board of WILEX AG effective
1 April 2014. Going forward, he will hold both posts and continue to serve
as Managing Director of Heidelberg Pharma GmbH. Dr Paul Bevan will remain
responsible for the Group's R&D activities and make himself available as
the main point of contract for licencing talks in connection with WILEX'

These decisions also reflect the re-positioning of WILEX. WILEX will focus
on the ADC technology and push the commercialisation of the clinical
development projects with a team of approximately 50 employees with
emphasis in Ladenburg.

Professor Olaf G. Wilhelm, CEO of WILEX AG, commented: "The necessary
cost-cutting programme will inevitably result in a company alignment
significantly limiting the freedom to shape its business which has been
both the goal and motivation of my entrepreneurial work from the company's
foundation until today. I thank all of our employees for their support -
especially in the last months."

Professor Christof Hettich, chairman of the Supervisory Board, commented:
"I would like to thank Professor Wilhelm for his dedicated work in the past
years. The Supervisory Board believes that the future focus of development
by the WILEX Group will be on the highly topical and promising antibody
drug conjugate technology developed and marketed by its subsidiary
Heidelberg Pharma. This ADC technology is one of the most promising
approaches worldwide in the area of these new cancer therapies. Heidelberg
Pharma has been successfully working on this technology for years. This
view is reflected in the decision regarding the future Group's management."

About WILEX 
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, WILEX develops diagnostic and therapeutic product candidates
for the specific detection and targeted treatment of various types of
cancer based on antibodies and small molecules. The subsidiary Heidelberg
Pharma GmbH in Ladenburg offers preclinical contract research services and
an antibody drug conjugate (ADC) technology platform. Our customers and
partners include leading international pharmaceutical companies. WILEX AG
is listed at the Frankfurt Stock Exchange. ISIN DE0006614720 / WKN 661472 /
Symbol WL6. More information is available at www.wilex.com.

Contact                                 For press enquiries
WILEX AG                                MC Services AG
Corporate Communications                Katja Arnold (CIRO)
Sylvia Wimmer                           Tel.: +49 (0)89-41 31 38-126
Tel.: +49 (0)89-41 31 38-29             Tel.: +49-89-210 228-40
Email: investors[at]wilex.com           Mobil: +49 160 9360 3022
Grillparzerstr. 10, 81675 Munich,       E-Mail: katja.arnold[at]mc-
Germany                                 services.eu

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "will" "should" "future", "potential" or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

End of Corporate News


24.02.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language:    English                                                
Company:     WILEX AG                                               
             Grillparzerstr. 10                                     
             81675 München                                          
Phone:       +49 (0)89 41 31 38 - 0                                 
Fax:         +49 (0)89 41 31 38 - 99                                
E-mail:      info@wilex.com                                         
Internet:    www.wilex.com                                          
ISIN:        DE0006614720                                           
WKN:         661472                                                 
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, München, Stuttgart  
End of News    DGAP News-Service  
254067 24.02.2014                                                      
Press spacebar to pause and continue. Press esc to stop.